Sanjivani Paranteral
206.60
-3.90(-1.85%)
Market Cap₹253.81 Cr
PE Ratio34.68
IndustryHealthcare
Company Performance:
1D-1.85%
1M+1.30%
6M-2.87%
1Y-30.83%
5Y+1,821.86%
View Company Insightsright
More news about Sanjivani Paranteral
08Sept 25
Sanjivani Parenteral Launches Commercial Production at New IV Fluid Plant in Pune
Sanjivani Parenteral Limited has started commercial production at its new intravenous fluid infusion plant in Pune, Maharashtra. The facility, operated by subsidiary SPL Infusion Pvt. Ltd., began operations on September 6, 2025. The plant features advanced technology, sustainability initiatives including solar panels, and has obtained necessary manufacturing licenses. Located strategically in Pune, it aims to serve both domestic and export markets efficiently.
 no imag found
18Aug 25
Sanjivani Parenteral Reports 8.9% Revenue Growth in Q1, Pune Facility Set for Commercial Production
Sanjivani Parenteral Limited, a WHO-GMP certified pharmaceutical company, reported Q1 revenue growth of 8.9% YoY to INR 17.90 crores. EBITDA increased by 10.8% to INR 2.70 crores, with margins improving to 15.00%. The company maintains a 73.70%-26.30% export-domestic revenue mix, exporting to over 25 countries. Their new Pune facility is expected to begin commercial production by early September. The company added 8 new products in Q1 and Q2 combined and is focusing on expanding in LATAM and French-speaking African markets. Despite logistical challenges, management remains optimistic, providing a full-year revenue guidance of INR 75-80 crores.
 no imag found
12Aug 25
Sanjivani Paranteral Reports 8.9% Revenue Growth in Q1 FY26, Driven by Strong Injectables Performance
Sanjivani Paranteral Limited reported an 8.9% year-over-year revenue growth to ₹178.90 crore for Q1 FY26. EBITDA increased by 10.8% to ₹26.80 crore, while PAT grew marginally by 1.0% to ₹17.30 crore. The injectables segment showed robust growth of 47.1%, but the oral segment declined by 11.1% due to shipment challenges. Exports constituted 73.7% of total revenue, with core markets in CIS, Middle East & Africa, and Latin America contributing significantly. The company remains focused on R&D and expanding its product portfolio to drive future growth.
 no imag found
Sanjivani Paranteral
206.60
-3.90
(-1.85%)
1 Year Returns:-30.83%
Industry Peers
Sun Pharmaceutical
1,700.50
(+0.18%)
Divis Laboratories
6,149.50
(-0.31%)
Torrent Pharmaceuticals
4,261.50
(+4.50%)
Cipla
1,356.40
(+1.87%)
Dr Reddys Laboratories
1,269.40
(+0.10%)
Lupin
2,221.50
(+1.01%)
Zydus Life Science
910.45
(+0.64%)
Mankind Pharma
2,083.30
(+1.11%)
Aurobindo Pharma
1,184.60
(+3.40%)
Alkem Laboratories
5,480.50
(+1.44%)